In the Article by Tara Gomes and colleagues,1 it was concluded that initiation of safer opioid supply (SOS) programmes was associated with improvements in the rate of opioid toxicities, all-cause emergency department visits, all-cause inpatient hospitalisations, incident infections, and non-primary care-related health-care costs. The benefits in these factors were attributed to the initiation of SOS, similar to what was seen in the matched methadone initiation cohort, with the exception that the SOS group had significantly higher rates of opioid toxicity.